Asterias Biotherapeutics Receives a New Rating from H.C. Wainwright

By Jason Carr

Asterias Biotherapeutics (NYSE: AST) received a Buy rating and a $11 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed yesterday at $1.85.

Selvaraju observed:

“We reiterate our Buy rating and 12-month price target of $11 on AST.”

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 2.4% and a 39.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Asterias Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.75 and a one-year low of $1.20. Currently, Asterias Biotherapeutics has an average volume of 187.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.